Judge Voids PDL Antibody Patent In MedImmune Suit

Law360, New York (January 10, 2011, 3:34 PM EST) -- A federal judge has dealt PDL BioPharma Inc. a major blow, invalidating a patent covering the engineering of antibodies and ruling that MedImmune LLC did not violate a licensing agreement with sales of its Synagis drug.

In a ruling that could cost PDL hundreds of millions of dollars in royalties, Judge Jeremy Fogel of the U.S. District Court for the Northern District of California found on Friday that U.S. Patent Number 6,180,370 is invalid as anticipated by prior art and held that MedImmune did not violate...
To view the full article, register now.